RCC highlights of ESMO 2023 Congress

Camillo Porta shares his thoughts about the most important novelties in RCC treatment. Studies such as: - Belzutifan/LITESPARK studies: LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced ccRCC, LITESPARK-005 study comparing belzutifan to everolimus in patients with previously treated advanced ccRCC - Toripalimab/RENOTORCH: a randomized, open-label, phase 3 study of toripalimab combined with axitinib versus sunitinib for the first line treatment of advanced RCC - TIDE-A study: a phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic RCC Video: https://medicaldigest.org/scientific-contents/interview:rcc-highlights-esmo-2023-congress